Can clarithromycin (Biaxin) be given to a patient with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clarithromycin is Safe in G6PD Deficiency

Clarithromycin can be given to patients with G6PD deficiency without special precautions, as it is not among the medications that cause hemolysis in these patients.

Medications Actually Contraindicated in G6PD Deficiency

Only seven medications have solid evidence for causing hemolysis and should be avoided 1:

  • Dapsone 2, 3, 1
  • Methylthioninium chloride (methylene blue) 2, 3, 1
  • Nitrofurantoin 1
  • Phenazopyridine 1
  • Primaquine 2, 4, 1
  • Rasburicase 3, 4, 1
  • Tolonium chloride (toluidine blue) 1

Why Clarithromycin is Safe

Clarithromycin (a macrolide antibiotic) does not appear on any contraindicated or high-risk medication lists for G6PD deficiency 2, 3, 5, 1. The most comprehensive evidence-based review found that many compounds have been wrongly cited as causing hemolysis simply because they were administered during infection-related hemolytic episodes 1.

Clinical Context

  • Penicillins (like amoxicillin) are explicitly safe in G6PD deficiency and can be used in normal therapeutic doses 3
  • Beta-lactam antibiotics (including cephalosporins like cefuroxime) have been used safely without routine monitoring 4
  • Real-world data from over 31,000 G6PD-deficient patients showed that many previously suspected medications (including various antibiotics) were prescribed safely without causing hemolysis 6

Important Caveats

  • Infections themselves can trigger hemolysis in G6PD-deficient patients, independent of medication use 7, 6
  • If hemolysis occurs during clarithromycin treatment, it is more likely due to the underlying infection rather than the antibiotic 1
  • Monitor for signs of hemolysis (jaundice, dark urine, fatigue, pallor) when treating any infection in G6PD-deficient patients, regardless of antibiotic choice 3, 4

Practical Recommendation

Prescribe clarithromycin at standard doses without G6PD-related restrictions. The confusion around medication safety in G6PD deficiency stems from outdated lists that lack evidence 1. Focus your caution on the seven definitively contraindicated medications listed above 1.

References

Guideline

Medications Contraindicated in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of G6PD Deficiency in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Cefuroxime Safety in G6PD Deficiency Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Can I give Zykast (antihistamine) to patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
Can ramipril (Angiotensin-Converting Enzyme (ACE) inhibitor) cause Creatine Phosphokinase (CPK) elevation in a patient with known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency?
Is Bromhexine safe in patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
Can a patient with Glucose-6-phosphate dehydrogenase (G6PD) deficiency take benzonatate?
Can silver sulfadiazine be given to a patient with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
What is the recommended management approach for a female of reproductive age with a hydatidiform mole, considering her past medical history and potential for gestational trophoblastic neoplasia?
Are high serum vitamin B12 (cobalamin) levels a disadvantage in an adult patient with no known medical history?
What is the risk of thrombotic manifestations, such as deep vein thrombosis (DVT) or pulmonary embolism (PE), in a patient with a history of liver disease, particularly those at risk for hepatocellular carcinoma (HCC), before developing HCC?
How many Transjugular Intrahepatic Portosystemic Shunt (TIPS) stents can be safely deployed during reinterventions in a patient with a history of liver disease, particularly those at risk for hepatocellular carcinoma (HCC)?
What are the typical biopsy findings in a patient with a skin lesion suspected to be Henoch-Schönlein purpura (HSP)?
What is the recommended treatment for a patient with costochondritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.